A randomized, investigator blind, split-face study of the efficacy of using tranexamic acid injection for the treatment of melasma
- Conditions
- Male or female patients aged 18-60 years with melasma on both sides of the face.malasma, tranexamic acid, intralesional injections
- Registration Number
- TCTR20240731005
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
1. Male or female, aged 18-60 years, diagnosed with facial melasma.
2. Volunteers with mild to severe melasma (mMASI 1-24) that is symmetrical and of equal severity (mMASI difference not exceeding 5) between both sides of the face, assessed using the mMASI score criteria.
1. Individuals with a history of allergic reactions to tranexamic acid or anesthetics.
2. Those who have used topical vitamin A derivatives or hydroquinone within 3 months prior to the study.
3. Individuals with a history of using other topical agents that affect skin color, such as arbutin, azelaic acid, kojic acid, or cosmetic products with skin-lightening properties within 4 weeks prior to the study.
4. Individuals with contact dermatitis, photosensitivity dermatitis, erythematous inflammation, skin infections, or other abnormal skin pigmentation issues besides melasma on the treatment area of the face.
5. Those who have undergone procedures like chemical peels or laser treatments on the research area of the face within 6 months before the study.
6. Individuals with a history of taking oral contraceptives or hormone therapy within 6 months before the study.
7. Pregnant or breastfeeding women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method